Cilostazol: improving walking distance in patients with intermittent claudication

References

• Hiatt WR. Medical treatment of peripheralarterial disease and claudication. N Engl J. Med 344, 1608–1621 (2001).
   PubMed Web of Science ®Google Scholar
• Fowkes F, Housley E, Cawood E et al Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. mt. J Epidemid 20, 384–392 (1991).
   Web of Science ®Google Scholar
• Kannel WB, McGee DI. Update on some epidemiological features on intermittent claudication. J. Am. Geriatr Soc. 33, 13–18 (1985).
   PubMed Web of Science ®Google Scholar
• Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc. Surg 23(1), 104–115 (1996).
   PubMed Web of Science ®Google Scholar
• Collinson DJ, Donnelly R Therapeutic angiogenesis in the lower limb: can biotechnology produce an effective collateral circulation? Eur J Vasc. Endovasc. Surg 28, 9–23 (2004).
   PubMed Web of Science ®Google Scholar
• Lederman RJ, Mendelsohn FO, Anderson RD et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial. Lancet 359, 2053–2058 (2002).
   PubMed Web of Science ®Google Scholar
• Donnelly R, Yeung JM. Management of intermittent claudication: the importance of secondary prevention. Eur. J. Vasc. Endovasc. Surg. 23,100-107 (2002).
   Google Scholar
• Donnelly R. Pletal: symptom relief in intermittent claudication. Prescriber 26–32 (2003).
   Google Scholar
• Gotoh F, Tohgi H, Hirai S et al. Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J. Stroke Cerebrovasc. Dis. 9, 147–157 (2000)
   PubMedGoogle Scholar
• Schrör K. The pharmacology of cilostazol. Diabetes Obes. Metab. 4, S14—S19 (2002).
   Web of Science ®Google Scholar
• Liu Y, Fong M, Cone J, Wang S, Yoshitake M, Kambayashi J. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J. Cardiovasc. Pharmacol 36, 351–360 (2000).
   PubMed Web of Science ®Google Scholar
• Chapman TM, Goa KL. Cilostazol. A review of its use in intermittent claudication. Am. J. Cardiovasc. Drugs 3(2), 117–138 (2003).
   PubMedGoogle Scholar
• Takahashi S, Oida K, Fujiwara R et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J. Cardiovasc. Pharmacol 20, 900–906 (1992).
   PubMed Web of Science ®Google Scholar
• Elam MB, Heckman J, Crouse JR et al Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler. Thromb. Vasc. Bid 18, 1942–1947 (1998).
   PubMed Web of Science ®Google Scholar
• Nishio Y, Kashiwagi A, Takahara N, Hidaka H, Kikkawa R Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumour necrosis factor-a in vascular endothelial cells. Harm. Metab. Res. 29, 491–495 (1997)
   PubMed Web of Science ®Google Scholar
• Aoki M, Morishita R, Hayashi S et al. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in a rat diabetes model. Diabetalogia 44, 1034–1042 (2001).
   PubMed Web of Science ®Google Scholar
• Lee T-M, Su S-F, Tsai C-H et al. Differential effects of cilostazol and pentoxyfilline on vascular endothelial growth factor in patients with intermittent claudication. Clin. Sci. (London) 101(3), 305–311 (2001).
   PubMed Web of Science ®Google Scholar
• Bramer SL, Forbes WE Mallikaarjun S. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients in with intermittent claudication resulting form peripheral arterial disease. Clin. Pharmacokinet. 37, 1–11 (1999).
   PubMed Web of Science ®Google Scholar
• Bramer SL, Forbes WP. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin. Pharmacokinet. 37(Suppl. 2), 113–123 (1999).
   Google Scholar
• Suni A, Forbes WP, Bramer SL. Effects of CYP3A inhibition on the metabolism of cilostazol. Clin. Pharmacokinet. 37,61–68 (1999).
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Bramer SL, Bortey E et al. Pharmacodynamic—pharmacokinetic interaction of aspirin with cilostazol. Clin. Pharmacol Ther. 63,231 (1998).
   Web of Science ®Google Scholar
• Mallikaarjun S, Mico BA, Forbes WP A pharmacokinetic and pharmacodynamic study of the potential interaction between cilostazol and warfarin. Pharm. Res. 14, S555 (1997).
   Google Scholar
• White DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J. Vasc. Surg. 38, 710–713 (2003).
   PubMed Web of Science ®Google Scholar
• Strandness DE Jr, Dalman RE, Panian S et al Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc. Endovasc. Surg 36(2), 83–91 (2002).
   PubMedGoogle Scholar
• Dawson DL, Cutler BS, Hiatt VIR et al. A comparison of cilostazol and pentoxyfilline for treating intermittent claudication. Am. J. Med. 109(7), 523–530 (2000).
   PubMed Web of Science ®Google Scholar
• •Large multicenter trial comparing the effects of cilostazol, placebo and pentoxifylline on treadmill walking distance.
   Google Scholar
• Beebe HG, Dawson DL, Cutler BS et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch. Intern. Med. 159(17), 2041–2050 (1999).
   PubMedGoogle Scholar
• Dawson DL, Cutler BS, Meissner MH et al Cilostazol has beneficial effects in treatment of intermittent claudication: results of a multicentre, randomized, prospective, double-blind trial. Circulation 98(7), 678–686 (1998).
   PubMed Web of Science ®Google Scholar
• Money SR, Herd JA, Isaacsohn JL et al Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral arterial disease. J. Vasc. Surg. 27(2), 267–274 (1998).
   PubMed Web of Science ®Google Scholar
• Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am. J. Cardiol 90,1314–1319 (2002).
   PubMed Web of Science ®Google Scholar
• Pratt CM. Analysis of the cilostazol safety database. Am. J. Cardiol 87(12A), D28—D33 (2001).
   PubMedGoogle Scholar
• Packer M, Carver JR, Rodeheffer RJ. et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J. Med. 325(3), 634–640 (1991).
   Google Scholar
• Cone J, Wang S, Tandon N et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J. Cardiovasc. Pharmacol. 34(4), 497–504 (1999).
   PubMed Web of Science ®Google Scholar
• •Demonstrates that cilostazol and milrinone, both phosphodiesterase-3 inhibitors, have different effects on cAMP levels, which in turn might explain why cilostazol has not been associated with the adverse cardiovascular effects noted with milrinone.
   Google Scholar